Clinical performance of two commercially available rapid antigen tests for influenza, RSV, and SARS-CoV-2 diagnostics
Microbiology Spectrum · 2025
DOI: 10.1128/spectrum.01630-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Laura E Savolainen und 5 weiteren Autor:innen. Beteiligte Einrichtung: NordLab, Oulu, Finland. Hauptthemen laut MEDLINE: Sensitivity and Specificity, Respiratory Syncytial Virus Infections, COVID-19, Influenza, Human. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Competitive State Research Financing of the Expert Responsibility Areas of Fimlab Laboratories, NordLab, Tampere Tuberculosis Foundation.
Abstract (Originalsprache)
Rapid antigen tests (RATs) might provide rapid, low-cost, and easy-to-perform choice to nucleic-acid amplification methods (NAAT) in point-of-care (POC) diagnostics of respiratory infections. The clinical performance of two commercial combo-RATs for influenza A and B, respiratory syncytial virus (RSV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) POC diagnostics, was assessed. RAT and real-time-PCR (RT-PCR) analysis were performed on 620 patients admitted to the emergency department due to respiratory symptoms. The sensitivity and specificity of the RATs compared with RT-PCR results were studied. The sensitivity of the RATs with respect to symptom duration was also estimated. The tested RAT1 showed sensitivities of 98.68%, 73,53%, and 44.44% for SARS-CoV-2, influenza A, and RSV, respectively, when the cycle threshold (Ct) values were
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NordLab, Oulu, Finland.
- NordLab, Rovaniemi, Finland.
- Mehiläinen Länsi-Pohja, Kemi, Finland.
- Wellbeing Cervices County of Lapland, Rovaniemi, Finland.
- University of Oulu, Oulu, Finland.
- Tampere University, Tampere, Finland.
ORCID-Profile: Laura E Savolainen, Ilkka S Junttila
Förderung
- Competitive State Research Financing of the Expert Responsibility Areas of Fimlab Laboratories
- NordLab
- Tampere Tuberculosis Foundation
Zitieren
APA
Savolainen, L. E., Peltola, J., Hilla, R., Åman, T., Broas, M., & Junttila, I. S. (2025). Clinical performance of two commercially available rapid antigen tests for influenza, RSV, and SARS-CoV-2 diagnostics. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01630-24
Vancouver
Savolainen LE, Peltola J, Hilla R, Åman T, Broas M, Junttila IS. Clinical performance of two commercially available rapid antigen tests for influenza, RSV, and SARS-CoV-2 diagnostics. Microbiology Spectrum. 2025. doi:10.1128/spectrum.01630-24
BibTeX
@article{Savolainen2025,
author = {Savolainen, Laura E and Peltola, Joanna and Hilla, Risto and Åman, Tapio and Broas, Markku and Junttila, Ilkka S},
title = {Clinical performance of two commercially available rapid antigen tests for influenza, RSV, and SARS-CoV-2 diagnostics},
journal = {Microbiology Spectrum},
year = {2025},
doi = {10.1128/spectrum.01630-24}
}
EUVIMED